Summit Therapeutics (SMMT) Debt to Equity: 2019-2024
Historic Debt to Equity for Summit Therapeutics (SMMT) over the last 2 years, with Mar 2024 value amounting to $2.26.
- Summit Therapeutics' Debt to Equity rose 201.93% to $2.26 in Q1 2024 from the same period last year, while for Mar 2024 it was $2.26, marking a year-over-year increase of 201.93%. This contributed to the annual value of $1.29 for FY2023, which is 67.04% down from last year.
- According to the latest figures from Q1 2024, Summit Therapeutics' Debt to Equity is $2.26, which was up 75.73% from $1.29 recorded in Q4 2023.
- In the past 5 years, Summit Therapeutics' Debt to Equity ranged from a high of $3.90 in Q4 2022 and a low of $0.39 during Q1 2022.
- Over the past 3 years, Summit Therapeutics' median Debt to Equity value was $0.84 (recorded in 2023), while the average stood at $1.42.
- Per our database at Business Quant, Summit Therapeutics' Debt to Equity crashed by 67.04% in 2023 and then surged by 201.93% in 2024.
- Over the past 3 years, Summit Therapeutics' Debt to Equity (Quarterly) stood at $3.90 in 2022, then tumbled by 67.04% to $1.29 in 2023, then surged by 201.93% to $2.26 in 2024.
- Its Debt to Equity stands at $2.26 for Q1 2024, versus $1.29 for Q4 2023 and $0.84 for Q2 2023.